Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity

Jennelle C. Hodge, Kathryn E. Pearce, Amy C. Clayton, Florin A. Taran, Elizabeth A Stewart

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective This study aimed to determine whether 1p deletion defines a subset of cellular leiomyomata (CL), which is a hypercellular variant of uterine leiomyomata that may have delayed malignant potential, and to correlate this genetic change with clinical and pathologic characteristics including those present in uterine sarcomas. Study Design Available CL cases at the Mayo Clinic (n = 101) and variant cases reported in another article (n = 16) were identified. Each case with sufficient tissue that met histologic criteria for CL when reviewed by a single pathologist underwent interphase fluorescence in situ hybridization to determine the presence of 1p deletion. Clinical characteristics of women with confirmed CL were compared on the basis of 1p deletion status using univariate analysis. Results Of the Mayo Clinic cohort of histologically confirmed CL, 23% had deletion of 1p. Women with this subset of CL, when compared to those without 1p deletion, were more likely to be postmenopausal (P =.049) and their uteri tended to be heavier (P =.039) with a larger dominant leiomyoma (P =.030). The pathologic features associated with 1p deletion were high cellularity (P =.036) and hyaline necrosis (P =.047), which remained significant after inclusion of the CL cases from a previously published series. Conclusion Deletion of 1p occurs in approximately one-quarter of CL cases. This genetic alteration is potentially associated with clinicopathologic features that are present in uterine sarcomas, which suggests a distinct clinical entity that may have malignant potential. Our findings are particularly pertinent considering the increased preference for uterine-sparing options in leiomyoma treatment, suggesting assessment of 1p deletion status in CL may influence clinical surveillance decisions.

Original languageEnglish (US)
JournalAmerican Journal of Obstetrics and Gynecology
Volume210
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Chromosome Deletion
Leiomyoma
Sarcoma
Hyalin
Monosomy 1p Chromosome 1
Inclusion Bodies
Interphase
Fluorescence In Situ Hybridization
Uterus
Necrosis

Keywords

  • cellular leiomyomata
  • chromosome 1p
  • FISH
  • leiomyosarcoma
  • uterine leiomyomata

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity. / Hodge, Jennelle C.; Pearce, Kathryn E.; Clayton, Amy C.; Taran, Florin A.; Stewart, Elizabeth A.

In: American Journal of Obstetrics and Gynecology, Vol. 210, No. 6, 2014.

Research output: Contribution to journalArticle

Hodge, Jennelle C. ; Pearce, Kathryn E. ; Clayton, Amy C. ; Taran, Florin A. ; Stewart, Elizabeth A. / Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity. In: American Journal of Obstetrics and Gynecology. 2014 ; Vol. 210, No. 6.
@article{74c94aacd023404c934d31cece044109,
title = "Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity",
abstract = "Objective This study aimed to determine whether 1p deletion defines a subset of cellular leiomyomata (CL), which is a hypercellular variant of uterine leiomyomata that may have delayed malignant potential, and to correlate this genetic change with clinical and pathologic characteristics including those present in uterine sarcomas. Study Design Available CL cases at the Mayo Clinic (n = 101) and variant cases reported in another article (n = 16) were identified. Each case with sufficient tissue that met histologic criteria for CL when reviewed by a single pathologist underwent interphase fluorescence in situ hybridization to determine the presence of 1p deletion. Clinical characteristics of women with confirmed CL were compared on the basis of 1p deletion status using univariate analysis. Results Of the Mayo Clinic cohort of histologically confirmed CL, 23{\%} had deletion of 1p. Women with this subset of CL, when compared to those without 1p deletion, were more likely to be postmenopausal (P =.049) and their uteri tended to be heavier (P =.039) with a larger dominant leiomyoma (P =.030). The pathologic features associated with 1p deletion were high cellularity (P =.036) and hyaline necrosis (P =.047), which remained significant after inclusion of the CL cases from a previously published series. Conclusion Deletion of 1p occurs in approximately one-quarter of CL cases. This genetic alteration is potentially associated with clinicopathologic features that are present in uterine sarcomas, which suggests a distinct clinical entity that may have malignant potential. Our findings are particularly pertinent considering the increased preference for uterine-sparing options in leiomyoma treatment, suggesting assessment of 1p deletion status in CL may influence clinical surveillance decisions.",
keywords = "cellular leiomyomata, chromosome 1p, FISH, leiomyosarcoma, uterine leiomyomata",
author = "Hodge, {Jennelle C.} and Pearce, {Kathryn E.} and Clayton, {Amy C.} and Taran, {Florin A.} and Stewart, {Elizabeth A}",
year = "2014",
doi = "10.1016/j.ajog.2014.01.011",
language = "English (US)",
volume = "210",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity

AU - Hodge, Jennelle C.

AU - Pearce, Kathryn E.

AU - Clayton, Amy C.

AU - Taran, Florin A.

AU - Stewart, Elizabeth A

PY - 2014

Y1 - 2014

N2 - Objective This study aimed to determine whether 1p deletion defines a subset of cellular leiomyomata (CL), which is a hypercellular variant of uterine leiomyomata that may have delayed malignant potential, and to correlate this genetic change with clinical and pathologic characteristics including those present in uterine sarcomas. Study Design Available CL cases at the Mayo Clinic (n = 101) and variant cases reported in another article (n = 16) were identified. Each case with sufficient tissue that met histologic criteria for CL when reviewed by a single pathologist underwent interphase fluorescence in situ hybridization to determine the presence of 1p deletion. Clinical characteristics of women with confirmed CL were compared on the basis of 1p deletion status using univariate analysis. Results Of the Mayo Clinic cohort of histologically confirmed CL, 23% had deletion of 1p. Women with this subset of CL, when compared to those without 1p deletion, were more likely to be postmenopausal (P =.049) and their uteri tended to be heavier (P =.039) with a larger dominant leiomyoma (P =.030). The pathologic features associated with 1p deletion were high cellularity (P =.036) and hyaline necrosis (P =.047), which remained significant after inclusion of the CL cases from a previously published series. Conclusion Deletion of 1p occurs in approximately one-quarter of CL cases. This genetic alteration is potentially associated with clinicopathologic features that are present in uterine sarcomas, which suggests a distinct clinical entity that may have malignant potential. Our findings are particularly pertinent considering the increased preference for uterine-sparing options in leiomyoma treatment, suggesting assessment of 1p deletion status in CL may influence clinical surveillance decisions.

AB - Objective This study aimed to determine whether 1p deletion defines a subset of cellular leiomyomata (CL), which is a hypercellular variant of uterine leiomyomata that may have delayed malignant potential, and to correlate this genetic change with clinical and pathologic characteristics including those present in uterine sarcomas. Study Design Available CL cases at the Mayo Clinic (n = 101) and variant cases reported in another article (n = 16) were identified. Each case with sufficient tissue that met histologic criteria for CL when reviewed by a single pathologist underwent interphase fluorescence in situ hybridization to determine the presence of 1p deletion. Clinical characteristics of women with confirmed CL were compared on the basis of 1p deletion status using univariate analysis. Results Of the Mayo Clinic cohort of histologically confirmed CL, 23% had deletion of 1p. Women with this subset of CL, when compared to those without 1p deletion, were more likely to be postmenopausal (P =.049) and their uteri tended to be heavier (P =.039) with a larger dominant leiomyoma (P =.030). The pathologic features associated with 1p deletion were high cellularity (P =.036) and hyaline necrosis (P =.047), which remained significant after inclusion of the CL cases from a previously published series. Conclusion Deletion of 1p occurs in approximately one-quarter of CL cases. This genetic alteration is potentially associated with clinicopathologic features that are present in uterine sarcomas, which suggests a distinct clinical entity that may have malignant potential. Our findings are particularly pertinent considering the increased preference for uterine-sparing options in leiomyoma treatment, suggesting assessment of 1p deletion status in CL may influence clinical surveillance decisions.

KW - cellular leiomyomata

KW - chromosome 1p

KW - FISH

KW - leiomyosarcoma

KW - uterine leiomyomata

UR - http://www.scopus.com/inward/record.url?scp=84901624232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901624232&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2014.01.011

DO - 10.1016/j.ajog.2014.01.011

M3 - Article

VL - 210

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -